Drug Type Biological products |
Synonyms- |
Target |
Mechanism CD123 modulators(Interleukin-3 receptor subunit alpha modulators), FLT3 modulators(Tyrosine-protein kinase receptor FLT3 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adult Acute Myeloblastic Leukemia | Preclinical | CN | 08 Apr 2022 |